172 related articles for article (PubMed ID: 25633290)
1. Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications.
Baldari S; Ubertini V; Garufi A; D'Orazi G; Bossi G
Cell Death Dis; 2015 Jan; 6(1):e1621. PubMed ID: 25633290
[TBL] [Abstract][Full Text] [Related]
2. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
3. MKK3 as oncotarget.
Bossi G
Aging (Albany NY); 2016 Jan; 8(1):1-2. PubMed ID: 26805700
[No Abstract] [Full Text] [Related]
4. MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer.
Stramucci L; Pranteda A; Stravato A; Amoreo CA; Pennetti A; Diodoro MG; Bartolazzi A; Milella M; Bossi G
Cell Death Dis; 2019 Nov; 10(11):842. PubMed ID: 31695024
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function.
Gurtner A; Starace G; Norelli G; Piaggio G; Sacchi A; Bossi G
J Biol Chem; 2010 May; 285(19):14160-9. PubMed ID: 20223820
[TBL] [Abstract][Full Text] [Related]
6. Gossypetin is a novel MKK3 and MKK6 inhibitor that suppresses esophageal cancer growth in vitro and in vivo.
Xie X; Liu K; Liu F; Chen H; Wang X; Zu X; Ma X; Wang T; Wu Q; Zheng Y; Bode AM; Dong Z; Kim DJ
Cancer Lett; 2019 Feb; 442():126-136. PubMed ID: 30391783
[TBL] [Abstract][Full Text] [Related]
7. Approaching the challenges of MKK3/p38delta MAPK targeting for therapeutic purpose in colorectal cancer.
Stramucci L; Bossi G
J Exp Clin Cancer Res; 2019 Dec; 38(1):504. PubMed ID: 31881903
[TBL] [Abstract][Full Text] [Related]
8. Role of MKK3 and p38 MAPK in cytokine-induced death of insulin-producing cells.
Makeeva N; Myers JW; Welsh N
Biochem J; 2006 Jan; 393(Pt 1):129-39. PubMed ID: 16097952
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.
Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M
Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412
[TBL] [Abstract][Full Text] [Related]
10. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.
Garufi A; Baldari S; Pettinari R; Gilardini Montani MS; D'Orazi V; Pistritto G; Crispini A; Giorno E; Toietta G; Marchetti F; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2020 Jun; 39(1):122. PubMed ID: 32605658
[TBL] [Abstract][Full Text] [Related]
11. The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells.
Garufi A; Ubertini V; Mancini F; D'Orazi V; Baldari S; Moretti F; Bossi G; D'Orazi G
J Exp Clin Cancer Res; 2015 Aug; 34(1):87. PubMed ID: 26297485
[TBL] [Abstract][Full Text] [Related]
12. Gambogic acid counteracts mutant p53 stability by inducing autophagy.
Foggetti G; Ottaggio L; Russo D; Monti P; Degan P; Fronza G; Menichini P
Biochim Biophys Acta Mol Cell Res; 2017 Feb; 1864(2):382-392. PubMed ID: 27899303
[TBL] [Abstract][Full Text] [Related]
13. Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
Yang X; Fan D; Troha AH; Ahn HM; Qian K; Liang B; Du Y; Fu H; Ivanov AA
Bioorg Med Chem; 2021 Sep; 45():116324. PubMed ID: 34333394
[TBL] [Abstract][Full Text] [Related]
14. PBA Preferentially Impairs Cell Survival of Glioblastomas Carrying mutp53 by Reducing Its Expression Level, Stabilizing wtp53, Downregulating the Mevalonate Kinase and Dysregulating UPR.
Romeo MA; Gilardini Montani MS; Benedetti R; Garufi A; D'Orazi G; Cirone M
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32290231
[TBL] [Abstract][Full Text] [Related]
15. Acriflavine enhances radiosensitivity of colon cancer cells through endoplasmic reticulum stress-mediated apoptosis.
Lim MJ; Ahn JY; Han Y; Yu CH; Kim MH; Lee SL; Lim DS; Song JY
Int J Biochem Cell Biol; 2012 Aug; 44(8):1214-22. PubMed ID: 22564437
[TBL] [Abstract][Full Text] [Related]
16. MAPK kinase 3 is a tumor suppressor with reduced copy number in breast cancer.
MacNeil AJ; Jiao SC; McEachern LA; Yang YJ; Dennis A; Yu H; Xu Z; Marshall JS; Lin TJ
Cancer Res; 2014 Jan; 74(1):162-72. PubMed ID: 24233520
[TBL] [Abstract][Full Text] [Related]
17. Degradation of mutant p53H175 protein by Zn(II) through autophagy.
Garufi A; Pucci D; D'Orazi V; Cirone M; Bossi G; Avantaggiati ML; D'Orazi G
Cell Death Dis; 2014 May; 5(5):e1271. PubMed ID: 24874727
[TBL] [Abstract][Full Text] [Related]
18. Wild-type p53 in cancer cells: when a guardian turns into a blackguard.
Kim E; Giese A; Deppert W
Biochem Pharmacol; 2009 Jan; 77(1):11-20. PubMed ID: 18812169
[TBL] [Abstract][Full Text] [Related]
19. Effects of sodium ferulate on amyloid-beta-induced MKK3/MKK6-p38 MAPK-Hsp27 signal pathway and apoptosis in rat hippocampus.
Jin Y; Fan Y; Yan EZ; Liu Z; Zong ZH; Qi ZM
Acta Pharmacol Sin; 2006 Oct; 27(10):1309-16. PubMed ID: 17007737
[TBL] [Abstract][Full Text] [Related]
20. APE1/Ref-1 enhances DNA binding activity of mutant p53 in a redox-dependent manner.
Cun Y; Dai N; Li M; Xiong C; Zhang Q; Sui J; Qian C; Wang D
Oncol Rep; 2014 Feb; 31(2):901-9. PubMed ID: 24297337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
